Brought to you by 
Array, Amgen sign diabetes, metabolic disorders deal
15 Feb 2001
Executive Summary
Amgen has licensed exclusive rights to optimize and develop chemistry services company Array BioPharma's small-molecule inhibitors to the phosphotyrosine phosphatase 1B (PTP1B) diabetes and metabolic disorders target.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Array, Amgen sign diabetes, metabolic disorders deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice